{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:31:11Z","timestamp":1772793071762,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early palliative\/pre-emptive intervention improves clinical outcomes and quality of life for patients with metastatic cancer. A previous signal-seeking randomized controlled trial (RCT) demonstrated that early upfront radiotherapy to asymptomatic or minimally symptomatic high-risk osseous metastases led to reduction in skeletal-related events (SREs), a benefit driven primarily by subgroup of high-risk spine metastasis. The current RCT aims to determine whether early palliative\/pre-emptive radiotherapy in patients with high-risk, asymptomatic or minimally symptomatic spine metastases will lead to fewer SREs within 1\u00a0year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a single-center, parallel-arm, in-progress RCT in adults (\u2265 18 years) with ECOG performance status 0\u20132 and asymptomatic or minimally symptomatic (not requiring opioids) high-risk spine metastases from histologically confirmed solid tumor malignancies with &gt;\u20095 sites of metastatic disease on cross-sectional imaging. High-risk spine metastases are defined by the following: (a) bulkiest disease sites \u2265 2 cm; (b) junctional disease (occiput to C2, C7-T1, T12-L2, L5-S1); (c) posterior element involvement; or (d) vertebral body compression deformity &gt;\u200950%. Patients are randomized 1:1 to receive either standard-of-care systemic therapy (arm 1) or upfront, early radiotherapy to \u2264 5 high-risk spine lesions plus standard-of-care systemic therapy (arm 2), in the form of 20\u201330 Gy of radiation in 2\u201310 fractions. The primary endpoint is SRE, a composite outcome including spinal fracture, spinal cord compression, need for palliative radiotherapy, interventional procedures, or spinal surgery. Secondary endpoints include (1) surrogates of health care cost, including the number and duration of SRE-related hospitalizations; (2) overall survival; (3) pain-free survival; and (4) quality of life. Study instruments will be captured pre-treatment, at baseline, during treatment, and at 1, 3, 6, 12, and 24\u00a0months post-treatment. The trial aims to accrue 74 patients over 2\u00a0years to achieve &gt;\u200980% power in detecting difference using two-sample proportion test with alpha &lt;\u20090.05.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results of this RCT will demonstrate the value, if any, of early radiotherapy for high-risk spine metastases. The trial has received IRB approval, funding, and prospective registration (NCT05534321) and has been open to accrual since August 19, 2022. If positive, the trial will expand the scope and utility of spine radiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.Gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05534321\">NCT05534321<\/jats:ext-link>. Registered September 9, 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial status<\/jats:title>\n                <jats:p>Version 2.0 of the protocol (2021-KOT-002), revised last on September 2, 2022, was approved by the WCG institutional review board (Study Number 1337188, IRB tracking number 20223735). The trial was first posted on ClinicalTrials.Gov on September 9, 2022 (NCT05534321). Patient enrollment commenced on August 19, 2022, and is expected to be completed in 2\u00a0years, likely by August 2024.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07850-8","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:02:05Z","timestamp":1705035725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Robert J.","family":"Rothrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Ozair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Avendano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyen","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Starosciak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Leon-Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6927-0402","authenticated-orcid":false,"given":"Rupesh R.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"8","key":"7850_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584\u201393.","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"7850_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/neuros\/nyaa380","volume":"88","author":"RJ Rothrock","year":"2021","unstructured":"Rothrock RJ, Barzilai O, Reiner AS, Lis E, Schmitt AM, Higginson DS, et al. Survival trends after surgery for spinal metastatic tumors: 20-year cancer center experience. Neurosurgery. 2021;88(2):402\u201312.","journal-title":"Neurosurgery."},{"issue":"22","key":"7850_CR3","doi-asserted-by":"publisher","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","volume":"35","author":"CG Fisher","year":"2010","unstructured":"Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010;35(22):E1221\u20139.","journal-title":"Spine (Phila Pa 1976)."},{"issue":"26","key":"7850_CR4","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.2014.55.1143","volume":"32","author":"ST Lutz","year":"2014","unstructured":"Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol. 2014;32(26):2913\u20139.","journal-title":"J Clin Oncol."},{"issue":"1","key":"7850_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(1):4\u201312.","journal-title":"Pract Radiat Oncol."},{"issue":"9930","key":"7850_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","volume":"383","author":"C Zimmermann","year":"2014","unstructured":"Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet. 2014;383(9930):1721\u201330.","journal-title":"Lancet."},{"issue":"4","key":"7850_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1227\/neu.0000000000002083","volume":"91","author":"RJ Rothrock","year":"2022","unstructured":"Rothrock RJ, Reiner AS, Barzilai O, Kim NC, Ogilvie SQ, Lis E, et al. Responder analysis of pain relief after surgery for the treatment of spinal metastatic tumors. Neurosurgery. 2022;91(4):604\u201317.","journal-title":"Neurosurgery."},{"issue":"5","key":"7850_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082\u201390.","journal-title":"Cancer."},{"issue":"11","key":"7850_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879\u201382.","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"7850_CR10","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613\u201321.","journal-title":"Cancer."},{"issue":"1","key":"7850_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","volume":"23","author":"A Stopeck","year":"2020","unstructured":"Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, et al. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020;23(1):37\u201347.","journal-title":"J Med Econ."},{"key":"7850_CR12","doi-asserted-by":"crossref","unstructured":"Duran I, Fink MG, Bahl A, Hoefeler H, Mahmood A, L\u00fcftner D, et al. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. Eur J Cancer Care (Engl). 2017:26(6).","DOI":"10.1111\/ecc.12452"},{"key":"7850_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/2193-1801-3-328","volume":"3","author":"D L\u00fcftner","year":"2014","unstructured":"L\u00fcftner D, Lorusso V, Duran I, Hechmati G, Garzon-Rodriguez C, Ashcroft J, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus. 2014;3:328.","journal-title":"Springerplus."},{"issue":"5","key":"7850_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ijrobp.2022.09.005","volume":"114","author":"EF Gillespie","year":"2022","unstructured":"Gillespie EF, Mathis NJ, Marine C, Zhang Z, Barker CA, Guttmann DM, et al. Prophylactic radiation therapy vs. standard-of-care for patients with high-risk, asymptomatic bone metastases: a multicenter, randomized phase II trial. Int J Radiat Oncol Biol Phys. 2022;114(5):1059.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"7850_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med."},{"issue":"23","key":"7850_CR16","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, et al. Guidelines for reporting outcomes in trial protocols: the SPIRIT-Outcomes 2022 extension. Jama. 2022;328(23):2345\u201356.","journal-title":"Jama."},{"issue":"5","key":"7850_CR17","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1200\/OP.22.00037","volume":"18","author":"N Ledesma Vicioso","year":"2022","unstructured":"Ledesma Vicioso N, Lin D, Gomez DR, Yang JT, Lee NY, Rimner A, et al. Implementation strategies to increase clinical trial enrollment in a community-academic partnership and impact on Hispanic representation: an interrupted time series analysis. JCO Oncol Pract. 2022;18(5):e780\u20135.","journal-title":"JCO Oncol Pract."},{"issue":"6","key":"7850_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/occmed\/kqw041","volume":"66","author":"J Stanhope","year":"2016","unstructured":"Stanhope J. Brief Pain Inventory review. Occup Med (Lond). 2016;66(6):496\u20137.","journal-title":"Occup Med (Lond)."},{"issue":"2","key":"7850_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0304-3959(99)00101-3","volume":"83","author":"MP Jensen","year":"1999","unstructured":"Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999;83(2):157\u201362.","journal-title":"Pain."},{"issue":"11","key":"7850_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/jnci\/dji139","volume":"97","author":"WF Hartsell","year":"2005","unstructured":"Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798\u2013804.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"7850_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570\u20139.","journal-title":"J Clin Oncol."},{"issue":"2","key":"7850_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0163278705275341","volume":"28","author":"PS Brucker","year":"2005","unstructured":"Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28(2):192\u2013211.","journal-title":"Eval Health Prof."},{"key":"7850_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1477-7525-11-203","volume":"11","author":"P Teckle","year":"2013","unstructured":"Teckle P, McTaggart-Cowan H, Van der Hoek K, Chia S, Melosky B, Gelmon K, et al. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health Qual Life Outcomes. 2013;11:203.","journal-title":"Health Qual Life Outcomes."},{"issue":"5","key":"7850_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med."},{"issue":"6","key":"7850_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2165\/00019053-199813060-00005","volume":"13","author":"X Badia","year":"1998","unstructured":"Badia X, Herdman M, Kind P. The influence of ill-health experience on the valuation of health. Pharmacoecon. 1998;13(6):687\u201396.","journal-title":"Pharmacoecon."},{"issue":"7","key":"7850_CR26","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"MF Janssen","year":"2013","unstructured":"Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717\u201327.","journal-title":"Qual Life Res."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07850-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07850-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07850-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:02:48Z","timestamp":1705035768000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07850-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7850"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07850-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"18 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (2021-KOT-002) was approved by the WCG institutional review board (Study Number 1337188, IRB tracking number 20223735) on 07\/25\/2022. Prior to study participation, written and informed consent for participation is obtained from all participants after risks and benefits have been explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provide consent for publication of this manuscript. The investigators will provide a model consent form and other study documents upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R. J. Rothrock: None. A. Ozair: None. M. C. Avendano: None. S. Herrera: None. H. R. Appel: Personal fees from Novocure Inc, and GT Medical Technologies. S. Ramos: None. A. K. Starosciak: Consulting for Viz.ai. D. Leon-Ariza: None. M. Rubens: None. M. W. McDermott: Consulting for Stryker, Zap surgical, Deinde Medical, Light Helmets. M. S. Ahluwalia: Grants from AstraZeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, MimiVax, Merck. Consulting for Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix. Scientific advisory board member for Cairn Therapeutics, Pyramid Biosciences, Modifi Biosciences. Stock shareholding in Mimivax, Cytodyn, MedInnovate Advisors LLC. M. P. Mehta: Consulting for Karyopharm, Tocagen, Astrazeneca, Blue Earth Diagnostics, Celgene, Abbvie; board of directors: Oncoceutics. R. R. Kotecha: Personal fees from Accuray Inc., Elekta AB, ViewRay Inc., Novocure Inc., Elsevier Inc., Brainlab, Kazia Therapeutics, Castle Biosciences, and institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, and Kazia Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}